Proper assessment and prognostication of patients with hepatocellular carcinoma.
作者信息
Giannini Edoardo G
机构信息
Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
Department of Internal Medicine, Digestive Diseases Section, Liver Center, Yale University School of Medicine, New Haven, Connecticut, USA.
出版信息
Clin Liver Dis (Hoboken). 2024 Mar 7;23(1):e0129. doi: 10.1097/CLD.0000000000000129. eCollection 2024 Jan-Jun.
Abstract
摘要
相似文献
1
Proper assessment and prognostication of patients with hepatocellular carcinoma.肝细胞癌患者的正确评估与预后判断
Clin Liver Dis (Hoboken). 2024 Mar 7;23(1):e0129. doi: 10.1097/CLD.0000000000000129. eCollection 2024 Jan-Jun.
2
Prognostication of Hepatocellular Carcinoma Using Artificial Intelligence.利用人工智能预测肝细胞癌。
Korean J Radiol. 2024 Jun;25(6):550-558. doi: 10.3348/kjr.2024.0070.
3
Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?甲胎蛋白在肝细胞癌中的作用：预后、治疗监测还是两者兼有？
Future Oncol. 2009 Aug;5(6):889-99. doi: 10.2217/fon.09.64.
4
Prognostication and risk factor stratification for survival of patients with hepatocellular carcinoma: a nationwide big data analysis.预测和风险因素分层对肝癌患者生存的影响：一项全国性大数据分析。
Sci Rep. 2023 Jun 27;13(1):10388. doi: 10.1038/s41598-023-37277-9.
5
Prognostication in hepatocellular carcinoma: is it a burden or a ticket?肝细胞癌的预后评估：它是一种负担还是一张通行证？
Br J Surg. 2021 Apr 30;108(4):337-339. doi: 10.1093/bjs/znaa167.
6
Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on "Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma".开启未来：机器学习为早期肝细胞癌的预后预测带来曙光：关于“早期肝细胞癌患者的传统及基于机器学习的风险评分”的社论
Clin Mol Hepatol. 2024 Oct;30(4):698-701. doi: 10.3350/cmh.2024.0327. Epub 2024 May 7.
7
New perspectives in prognostication of hepatocellular carcinoma: The role and clinical implications of transient receptor potential family genes.肝细胞癌预后的新视角：瞬时受体电位家族基因的作用及临床意义
World J Gastrointest Oncol. 2024 Jun 15;16(6):2862-2864. doi: 10.4251/wjgo.v16.i6.2862.
8
Hepatocellular tumors: immunohistochemical analyses for classification and prognostication.肝细胞肿瘤：用于分类和预后判断的免疫组织化学分析。
Chin J Cancer Res. 2011 Dec;23(4):245-53. doi: 10.1007/s11670-011-0245-6.
9
10
The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma.开发与再生相关的 microRNA 作为生物标志物以改善肝功能衰竭综合征和肝细胞癌预后的挑战和潜力。
Expert Rev Mol Diagn. 2024 Jan-Feb;24(1-2):5-22. doi: 10.1080/14737159.2023.2292642. Epub 2023 Dec 19.
引用本文的文献
1
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?地中海地区肝细胞癌流行病学的变化：对监测的挑战？
JHEP Rep. 2025 Mar 12;7(7):101396. doi: 10.1016/j.jhepr.2025.101396. eCollection 2025 Jul.
2
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis.自身免疫性肝炎患者肝细胞癌的特征与转归
Dig Dis Sci. 2025 May 3. doi: 10.1007/s10620-025-09064-1.
本文引用的文献
1
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.阿替利珠单抗/贝伐单抗在肝功能受损的肝细胞癌患者中的安全性和疗效：一项系统评价和荟萃分析。
Liver Cancer. 2023 Oct 14;13(3):227-237. doi: 10.1159/000533991. eCollection 2024 Jun.
2
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的白蛋白-胆红素分级分析：III期IMbrave150研究的事后分析
Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. eCollection 2023 Oct.
3
HCC in peri-transplant period: What a gastroenterologist needs to know.肝移植围手术期的肝细胞癌：胃肠病学家需要了解的内容。
Clin Liver Dis (Hoboken). 2023 Jul 7;22(1):7-9. doi: 10.1097/CLD.0000000000000071. eCollection 2023 Jul.
4
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs.过去15年酒精相关肝细胞癌的情况凸显了扩大监测项目的必要性。
JHEP Rep. 2023 May 5;5(8):100784. doi: 10.1016/j.jhepr.2023.100784. eCollection 2023 Aug.
5
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept.肝细胞癌患者的个性化管理：一种多参数治疗分级概念
Lancet Oncol. 2023 Jul;24(7):e312-e322. doi: 10.1016/S1470-2045(23)00186-9.
6
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌预防、诊断和治疗实践指南。
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
7
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.基于美国多中心 HCC 移植协作组的研究：建立并验证肝移植术后肝细胞癌患者复发模型（RELAPSE）
Liver Transpl. 2023 Jul 1;29(7):683-697. doi: 10.1097/LVT.0000000000000145. Epub 2023 Apr 10.
8
Screening of liver cancer with abbreviated MRI.肝癌的 MRI 简化筛查。
Hepatology. 2023 Aug 1;78(2):670-686. doi: 10.1097/HEP.0000000000000339. Epub 2023 Mar 13.
9
Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence.肝移植术后肝细胞癌的复发率和死亡率：基于真实世界证据的Meta分析和系统评价
Cancers (Basel). 2022 Oct 19;14(20):5114. doi: 10.3390/cancers14205114.
10
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook.肝细胞癌的整体化管理：肝病学家的综合诊疗手册。
Liver Int. 2022 Dec;42(12):2607-2619. doi: 10.1111/liv.15432. Epub 2022 Oct 11.
Zotero 插件